Inflammatory B cells correlate with failure to checkpoint blockade in melanoma patients.
Kaat de JongeLaure TilléJoao LourencoHélène Maby-El HajjamiSina NassiriJulien RacleDavid GfellerMauro DelorenziGrégory VerdeilPetra BaumgaertnerDaniel E SpeiserPublished in: Oncoimmunology (2021)
The understanding of the role of B cells in patients with solid tumors remains insufficient. We found that circulating B cells produced TNFα and/or IL-6, associated with unresponsiveness and poor overall survival of melanoma patients treated with anti-CTLA4 antibody. Transcriptome analysis of B cells from melanoma metastases showed enriched expression of inflammatory response genes. Publicly available single B cell data from the tumor microenvironment revealed a negative correlation between TNFα expression and response to immune checkpoint blockade. These findings suggest that B cells contribute to tumor growth via the production of inflammatory cytokines. Possibly, these B cells are different from tertiary lymphoid structure-associated B cells, which have been described to correlate with favorable clinical outcome of cancer patients. Further studies are required to identify and characterize B cell subsets and their functions promoting or counteracting tumor growth, with the aim to identify biomarkers and novel treatment targets.
Keyphrases
- inflammatory response
- poor prognosis
- rheumatoid arthritis
- end stage renal disease
- skin cancer
- newly diagnosed
- single cell
- genome wide
- ejection fraction
- chronic kidney disease
- dna damage
- gene expression
- prognostic factors
- rna seq
- cell cycle
- long non coding rna
- big data
- machine learning
- electronic health record
- lipopolysaccharide induced
- peripheral blood
- basal cell carcinoma
- patient reported outcomes
- immune response
- lps induced
- dna methylation
- deep learning
- case control